ReviewProstate cancer and prostatic diseases2018
MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years.
Review in Prostate cancer and prostatic diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Proclarix, A New Biomarker for the Diagnosis of Clinically Significant Prostate Cancer: A Systematic Review.Molecular diagnosis & therapy · 2022Pooled it
- Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.European urology oncology · 2019Pooled it
- Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis.Prostate cancer and prostatic diseases · 2019Pooled it
- Predictive Value of Multiparametric Magnetic Resonance Imaging (T2-weighted Imaging and Apparent Diffusion Coefficient) for Pathological Grading of Prostate Cancer: a Meta-Analysis.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- The Role of Micro-Ultrasound in Prostate Cancer Detection.Current urology reports · 2026Review
- Association of PI-RADS Score with Clinically Significant Prostate Cancer and Histopathological Upgrading in Patients Undergoing Radical Prostatectomy: A Retrospective Single-Centre Study.Journal of clinical medicine · 2026Article
- Is targeted biopsy necessary for Prostate Imaging Reporting and Data System 3 lesions?Revista da Associacao Medica Brasileira (1992) · 2026Article
- Should systematic prostatic biopsies be discontinued?Prostate cancer and prostatic diseases · 2025Review
- Prostate cancer detection rate with MRI-targeted biopsy alone using outpatient transperineal prostate biopsy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither?BMC urology · 2024Article
- Therapy decisions after diagnosis of prostate cancer in men with negative prostate MRI.The Prostate · 2023Article
- Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study).European urology open science · 2023Article
- Segmentation of the prostate, its zones, anterior fibromuscular stroma, and urethra on the MRIs and multimodality image fusion using U-Net model.Quantitative imaging in medicine and surgery · 2022Article
- Artificial Intelligence Algorithm-Based MRI for Differentiation Diagnosis of Prostate Cancer.Computational and mathematical methods in medicine · 2022Article
- Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series.Prostate cancer and prostatic diseases · 2021Article
- MRI and Targeted Biopsy Essential Tools for an Accurate Diagnosis and Treatment Decision Making in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2021Review
- Comparison of Accuracies between Real-Time Nonrigid and Rigid Registration in the MRI-US Fusion Biopsy of the Prostate.Diagnostics (Basel, Switzerland) · 2021Article
- Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China.Medical science monitor : international medical journal of experimental and clinical research · 2021Observational
- Cost-effectiveness of multiparametric magnetic resonance imaging and MRI-guided biopsy in a population-based prostate cancer screening setting using a micro-simulation model.Cancer medicine · 2021Article
- Transrectal versus transperineal prostate biopsy under intravenous anaesthesia: a clinical, microbiological and cost analysis of 2048 cases over 11 years at a tertiary institution.Prostate cancer and prostatic diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn recent years, evidence has accrued to support the introduction of multiparametric magnetic resonance imaging (mpMRI) in the prostate cancer diagnostic pathway. The exact role of mpMRI in different settings is not widely agreed. In this review, we look at the use of MRI in three groups of men: biopsy naive men, those with a previous negative biopsy and those with a previous positive biopsy suitable for active surveillance. MATERIAL AND
methodsAn electronic MEDLINE/PubMed search up to 24th January 2018 was performed, using the search terms (prostate cancer OR prostate adenocarcinoma) AND (MRI OR magnetic resonance) AND (biopsy naive OR active surveillance OR prior negative biopsy OR no prior biopsy). Only those studies which reported detection rates of standard biopsy and MRI-targeted biopsy, where all men had both an MRI and standard biopsy were included.
resultsIn total 34 articles were included (14 biopsy naive, 10 prior negative biopsy, and 10 prior positive biopsy). MRI-targeted biopsy consistently resulted in greater detection of clinically significant prostate cancer, and a lower detection of clinically insignificant prostate cancer, across all three patient populations. This effect was most prominent in men with at least one previous negative biopsy, and least prominent in men on active surveillance. In the presence of a negative mpMRI detection of csPCa found at systematic biopsy ranged from 0 to 20%.
conclusionsMRI-targeted biopsy is more efficient than standard biopsy in detecting clinically significant disease in men with a positive MRI, and results in less detection of clinically insignificant cancer. In men with a negative MRI, a significant minority of men will have clinically significant cancer detected on systematic biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.